Clinical prediction of failure of lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5511-5519

  Kim, In Kyoung ^a   Kim, Byeong Gwan ^a   Kim, Won ^a   Kim, Donghee ^b   Kim, Yoon Jun ^a   Yoon, Jung Hwan ^a   Lee, Hyo Suk ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTHRACYCLINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RITUXIMAB; STEROID;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; VIREMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TREATMENT FAILURE; VIRAL LOAD;

EID: 84868021840     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00821-12     Document Type: Article

References (31)

1. Artz AS, et al. 2010. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J. Clin. Oncol. 28:3199-3202.
2. Chun J, et al. 2010. High viremia, prolonged lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am. J. Transplant. 10:1649-1659.
3. Chung GE, et al. 2011. Add-on adefovir is superior to a switch to entecavir as rescue therapy for lamivudine-resistant chronic hepatitis B. Dig. Dis. Sci. 56:2130-2136.
4. Dienstag JL, et al. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
5. Evens AM, et al. 2011. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann. Oncol. 22:1170-1180.
6. Fine J, Gray R. 1999. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94:496-497.
7. Grambsch P, Therneau T. 1994. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515.
8. Hothorn T, Hornik K, Zeileis A. 2006. Unbiased recursive partitioning: a conditional inference framework. J. Comput. Graph. Stat. 15:651-674.
9. Hsu C, et al. 2008. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 47:844-853.
10. Hui CK, et al. 2005. Hepatitis B reactivation after withdrawal of preemptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54:1597-1603.
11. Jang JW, et al. 2006. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 43:233-240.
12. Kohrt HE, Ouyang DL, Keeffe EB. 2006. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment. Pharmacol. Ther. 24:1003-1016.
13. Lai CL, et al. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339:61-68.
14. Lai CL, et al. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696.
15. Lau GK, et al. 2002. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99:2324-2330.
16. Lau GK, et al. 2003. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742-1749.
17. Li YH, et al. 2006. Lamivudine prophylaxis reduces the incidence and severity ofhepatitis in hepatitis Bvirus carriers who receive chemotherapy for lymphoma. Cancer 106:1320-1325.
18. Lim LL, et al. 2002. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment. Pharmacol. Ther. 16:1939-1944.
19. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661-662.
20. Loomba R, et al. 2008. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 148:519-528.
21. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. 2002. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase- dependent mechanism. Blood 99:1314-1319.
22. Persico M, et al. 2002. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 99:724-725.
23. Prentice RL, Gloeckler LA. 1978. Regression analysis of grouped survival data with application to breast cancer data. Biometrics 34:57-67.
24. Rossi G, Pelizzari A, Motta M, Puoti M. 2001. Primary prophylaxis with lamivudine of hepatitis Bvirus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br. J. Haematol. 115: 58-62.
25. Therneau T, Grambsch P. 2000. Modeling survival data: extending the Cox model. Springer Verlag, Berlin, Germany.
26. Wursthorn K, Wedemeyer H, Manns MP. 2010. Managing HBV in patients with impaired immunity. Gut 59:1430-1445.
27. Yeo W, et al. 2004. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J. Clin. Oncol. 22:927-934.
28. Yeo W, et al. 2009. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 27:605-611.
29. Yeo W, et al. 2004. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br. J. Cancer 90:1306-1311.
30. Yuen MF, et al. 2001. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34:785-791.
31. Yun J, et al. 2011. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br. J. Cancer 104:559-563.